Bathi saben saham sajrone rolas wulan pungkasan: Zentalis Pharma (ZNTL)

ZNTL (Zentalis Pharmaceuticals, Inc.) - tandha merek perusahaan

Zentalis Pharmaceuticals (ZNTL) relies on a stable staff of leading oncologists and chemists. Net income per share over the last 12 months demonstrates local dynamics, with the value holding at -1.92. The business is based on non-cyclical demand in breast cancer therapy, utilizing external CRO and CMO capacities to minimize operational risks during the development of new molecules.

ZNTL (Zentalis Pharma) riwayat Bathi resik saben saham sajrone 12 wulan pungkasan saka 04.07.2022 nganti 18.11.2026

Rincian analitis perusahaan Zentalis Pharmaceuticals (ZNTL)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analisis perusahaan:Zentalis Pharma (ZNTL)
Produk seri Zentalis Pharma

Net income per share (TTM) serves as a fundamental filter to separate the underlying trend from market noise. This metric normalizes the company's total income by the number of securities, allowing for a comparison of business efficiency against industry benchmarks. The current trailing twelve-month earnings per share value is -1.92. This figure reflects the financial stability of Zentalis Pharmaceuticals (ZNTL). The brand's high scientific authority in oncology therapy determines the long-term dynamics of this profitability.